Information

We invited patients who were admitted to hospital with COVID-19 to take part in HEAL-COVID. Patients were asked if they wanted to take part shortly before they were discharged home, and were randomly allocated to receive:

Arm 1 (2021-2022): Apixaban, an anticoagulant, once a day for 12  months or

The usual standard care offered by their hospital, as appropriate to their symptoms and conditions.

Arm 2 (2022 – 2023): Atorvastatin, a statin with anti-inflammatory properties, once a day for 12 months or

The usual standard care offered by their hospital, as appropriate to their symptoms and conditions.

HEAL-COVID participants were also invited to complete follow-up surveys. This was optional. Surveys could be completed via an app on a smartphone or tablet, or over the phone with a Research Nurse. The surveys were sent no more frequently than once a week, and included questions relating to symptoms, quality of life, resource use and experience of participating in research.

While the main objective of the trial is to find out if the treatments used are effective, and help improve care for COVID-19 patients in the future, we will also use data from the study to investigate whether the treatments are cost-effective.

Your site was provided with log-in details when they got greenlight to open. These details allow access to the researcher area, containing training materials and ISF documents.

Please get in touch if you cannot find the information you need.

NHS England and Improvement and the Devolved Nations support all UK approved platform studies. For the HEAL-COVID trial and the provision of atorvastatin, use in Secondary Care is considered in tariff and no further reimbursement is required. For ongoing prescribing of atorvastatin, logistics are still to be agreed, but costs will be picked up via normal BAU systems.